KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients ^(1-4)

Patients with HR+/HER2– EBC: ^(1,3)

High-risk node negative

N0, T2

Grade 2 with high-risk features*
Grade 3

N0, T3-4

ALL PATIENTS

All node positive

ALL PATIENTS

N2-3

ALL PATIENTS

* Of all approved CDK4/6i. ^(1-4)

^‡ Grade 3 or grade 2 with additional risk factors, such as Ki-67 score ≥20% or defined as an Oncotype DX Breast Recurrence Score of ≥26, or Prosigna/PAM50, MammaPrint, or EndoPredict EPclin high-risk scores. ⁽³⁾

Abbreviations & References

Eligible patients

KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients (1-4)

KISQALI: approved in the broadest * population including all N+ and high-risk N0 patients ^(1-4)